GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » ViaDerma Inc (OTCPK:VDRM) » Definitions » Capex-to-Operating-Cash-Flow

ViaDerma (ViaDerma) Capex-to-Operating-Cash-Flow : 0.98 (As of Jun. 2012)


View and export this data going back to 2008. Start your Free Trial

What is ViaDerma Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

ViaDerma's Capital Expenditure for the three months ended in Jun. 2012 was $-2.00 Mil. Its Cash Flow from Operations for the three months ended in Jun. 2012 was $2.03 Mil.

Hence, ViaDerma's Capex-to-Operating-Cash-Flow for the three months ended in Jun. 2012 was 0.98.


ViaDerma Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for ViaDerma's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ViaDerma Capex-to-Operating-Cash-Flow Chart

ViaDerma Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11
Capex-to-Operating-Cash-Flow
- 1.08 1.67 0.92 1.56

ViaDerma Quarterly Data
Sep07 Dec07 Mar08 Jun08 Sep08 Dec08 Mar09 Jun09 Sep09 Dec09 Mar10 Jun10 Sep10 Dec10 Mar11 Jun11 Sep11 Dec11 Mar12 Jun12
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.12 - 0.54 0.27 0.98

Competitive Comparison of ViaDerma's Capex-to-Operating-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, ViaDerma's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ViaDerma's Capex-to-Operating-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, ViaDerma's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where ViaDerma's Capex-to-Operating-Cash-Flow falls into.



ViaDerma Capex-to-Operating-Cash-Flow Calculation

ViaDerma's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2011 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-9.432) / 6.054
=1.56

ViaDerma's Capex-to-Operating-Cash-Flow for the quarter that ended in Jun. 2012 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (-1.996) / 2.033
=0.98

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ViaDerma  (OTCPK:VDRM) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


ViaDerma Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of ViaDerma's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


ViaDerma (ViaDerma) Business Description

Traded in Other Exchanges
N/A
Address
4640 Admiralty Way, Suite 500, Marina Del Rey, CA, USA, 90292
ViaDerma Inc is a specialty pharmaceutical company focused to bring new products to market through research and development. It is engaged in the business of manufacturing and sales of pharmaceuticals, and specifically topical antibiotics and pain management in the United States of America. Its sells under the brand name Vitastem. The Company also has products in development in the fields; anti-aging skin care, pain management, hair-loss, and toenail fungus.